

Resource Summary Report

Generated by RRID on Jul 29, 2026

CD3

RRID:AB_2744383

Type: Antibody

Proper Citation

BD Biosciences Cat# 563797, RRID:AB_2744383

Antibody Information

URL: http://antibodyregistry.org/AB_2744383

Proper Citation: BD Biosciences Cat# 563797, RRID:AB_2744383

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: SK7 (also known as Leu-4)

Antibody ID: AB_2744383

Vendor: BD Biosciences

Catalog Number: 563797

Alternative Catalog Numbers: 563798

Record Creation Time: 20250820T004449+0000

Record Last Update: 20250820T090520+0000

Ratings and Alerts

No rating or validation information has been found for CD3.

No alerts have been found for CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

van der Sluis RM, et al. (2025) Distinctive CD8+ T cell activation by antigen-presenting plasmacytoid dendritic cells compared to conventional dendritic cells. *Cell reports*, 44(3), 115413.

Caulier B, et al. (2024) CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. *Cell reports. Medicine*, 5(6), 101572.

Zoine JT, et al. (2024) Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity. *Cell reports. Medicine*, 5(2), 101422.

Cronin S, et al. (2024) The immunosuppressive tuberculosis-associated microenvironment inhibits viral replication and promotes HIV-1 latency in CD4+ T cells. *iScience*, 27(7), 110324.

Lameris R, et al. (2023) Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions. *Journal for immunotherapy of cancer*, 11(12).

Lameris R, et al. (2023) A bispecific T cell engager recruits both type 1 NKT and V α 9V β 2-T cells for the treatment of CD1d-expressing hematological malignancies. *Cell reports. Medicine*, 4(3), 100961.

Frentzas S, et al. (2023) A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors. *Cell reports. Medicine*, 4(11), 101242.

Henning AN, et al. (2023) Peripheral B cells from patients with hepatitis C virus-associated lymphoma exhibit clonal expansion and an anergic-like transcriptional profile. *iScience*, 26(1), 105801.

Gabriely G, et al. (2021) Myeloid cell subsets that express latency-associated peptide promote cancer growth by modulating T cells. *iScience*, 24(11), 103347.

Ott PA, et al. (2020) A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. *Cell*, 183(2), 347.

Argüello RJ, et al. (2020) SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell Resolution. *Cell metabolism*, 32(6), 1063.

Poran A, et al. (2020) Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. *Cell reports. Medicine*, 1(8), 100141.